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Abstract
Background
Replicating smallpox vaccines can cause severe complications in individuals with atopic
dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-repli-
cating vaccine in humans, showed a favorable safety and immunogenicity profile in healthy
volunteers.
Objective
This Phase II study compared the safety and immunogenicity of MVA enrolling groups of
350 subjects with AD (SCORAD 30) and 282 healthy subjects.
Methods
Subjects were vaccinated twice with MVA, each dose given subcutaneously 4 weeks apart.
Adverse events, cardiac parameters, and the development of vaccinia virus humoral
immune responses were monitored.
Results
The overall safety of the vaccine was similar in both groups. Adverse events affecting skin
were experienced significantly more often in subjects with AD, but the majority of these
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events were mild to moderate in intensity. Seroconversion rates and geometric mean titers
for total and neutralizing vaccinia-specific antibodies in the AD group were non-inferior com-
pared to the healthy subjects.
Limitations
The size of the study population limited the detection of serious adverse events occurring at
a frequency less than 1%.
Conclusion
MVA has a favorable safety profile and the ability to elicit vaccinia-specific immune
responses in subjects with AD.
Trial Registration
ClinicalTrials.gov NCT00316602
Introduction
Smallpox is caused by Variola virus (VARV), an orthopoxvirus of the Poxviridae family. The
disease was declared eradicated in 1980 by the World Health Organization (WHO). Serious
concerns about the re-emergence of VARV persist and have led the US government to assess
the potential reoccurrence of smallpox as a major bioterrorism threat [1.2].
Traditional smallpox vaccines contain replication-competent vaccinia virus (VACV), an
orthopoxvirus related to VARV [1,2]. These vaccines are administered via scarification to the
skin, causing a localized VACV infection that elicits a protective immune response to VARV.
Although these vaccines are highly effective, their replication-competent nature can cause mor-
bidity or even mortality. Skins complications include progressive vaccinia, eczema vaccinatum
(EV), generalized vaccinia and autoinoculation [3–5].
Individuals with eczema, Atopic Dermatitis (AD) or a history of these conditions are at an
increased risk of developing EV [6–8]. Historically, EV occurred at a rate of 39 cases per mil-
lion vaccinations in the general population and was not limited to the vaccine recipients as con-
tact transmission of VACV is possible [4,5]. Virus shedding following vaccination places
individuals in contact with vaccine recipients at risk; there is evidence that EV may be more
severe in contacts compared to vaccine recipients [4,9–11]. These observations led the Centers
for Disease Control and Prevention Advisory Committee on Immunization Practices to advise
against the use of traditional smallpox vaccines in individuals with skin disorders including
eczema, active AD, a history of eczema or AD, and individuals who have household contacts
with skin disorders.
The prevalence of skin disorders like AD or eczema could pose a serious challenge to any
large-scale vaccination program that relies upon traditional smallpox vaccines. A recent survey
of eczema prevalence in the USA found that as many as 31.6 million individuals met the empir-
ical definition of eczema (i.e., itching and inflamed rash, excessive dryness, skin fold location,
symptoms lasting 14 days, or associated with a physician diagnosis of asthma or of allergic
rhinitis or hay fever) and 17.8 million met the more rigorous criteria for AD [12]. Further com-
plicating any smallpox vaccination program is the observation that individual recollections
regarding a history of eczema or AD are unreliable. Studies suggest that 20–40% of individuals
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do not report that they or a close contact suffered from eczema or AD, even when medical rec-
ords confirm the contrary [13,14]. Given the various contraindications (e.g. AD, HIV infec-
tion), up to 25% of the population would have to be excluded from vaccination [15]. Therefore
there remains a need for a vaccine that can be used in individuals at increased risk of develop-
ing severe vaccine related complications.
MVA was used during the 1970s in more than 120,000 people for priming prior to adminis-
tration with a traditional smallpox vaccine [16,17]. MVA was derived from the parental
VACV, chorioallantois vaccinia Ankara, and essentially became replication restricted to avian
and certain non-human mammalian cells [18]. MVA is being developed as a safer stand-alone
smallpox vaccine. Clinical studies so far have shown that MVA is well tolerated in healthy
adults and those with HIV and induces immune responses comparable to traditional smallpox
vaccines [19–23]. These clinical data are supported by similar findings in animal models [24–
27]. Sera fromMVA vaccinated subjects neutralize VARV [28]. In a phase I clinical trial, sub-
jects with mild AD tolerated MVA well and had humoral immune responses comparable to
responses in healthy individuals [23]. We report the results of a Phase II clinical trial more
thoroughly investigating the safety and immunogenicity of MVA in individuals with mild to
moderate AD or a history of AD. The primary objective of the trial was to assess the humoral
immune response induced by MVA in subjects with diagnosed atopic dermatitis compared to
healthy subjects measured by an enzyme-linked immunosorbent assay (ELISA). The primary
hypothesis is that the humoral immune response of the group with diagnosed atopic dermatitis
was not statistically inferior compared to the group with healthy subjects, using the seroconver-
sion rate measured with ELISA 2 weeks after the second vaccination with MVA as the primary
endpoint. The main secondary safety objective was to detect all adverse events in the atopic
dermatitis group with an incidence of at least 1:100 with at least 95% probability. Other second-
ary objectives were the comparison of safety and reactogenicity in both groups.
Methods
Study design and subjects
MVA smallpox vaccine (IMVAMUNE) was produced by IDT Biologika GmbH (Dessau-
Roßlau, Germany) according to GMP and provided by Bavarian Nordic A/S (Kvistgaard, Den-
mark) in aliquots of 0.5 ml liquid-frozen vaccine containing at least 1 x 108 TCID50/ml. Sub-
jects were immunized at Weeks 0 and 4 by subcutaneous injection of a 0.5 ml dose.
This controlled, open-label Phase II study was conducted under an FDA IND. Enrollment
of 18–40 year old vaccinia-naïve volunteers took place at 17 sites in the USA and 7 sites in
Mexico, all according to Good Clinical Practice and the principles of the Declaration of
Helsinki.
Subjects enrolled in the control group were healthy without any history of atopy; subjects
enrolled for the group under investigation were diagnosed with AD. The latter included sub-
jects with a documented history of AD with no symptoms for at least one year prior to enroll-
ment, as well as subjects with active AD having a SCORAD 30 [29]. The first subject was
screened in July 2006. The last screening took place in January 2009, the last regular study visit
in April 2009 and the last follow up visit in October 2009.
The protocol was approved by independent ethics committees for each site and all volun-
teers provided written informed consent prior to participation in the clinical trial. Approval
was granted by the following committees: Comité de Investigación. para Estudios en Humanos,
Puente de Piedra No.150, Col. Toriello Guerra, Tlalpan Mexico City, Mexico 14050; Comité de
Ética del Instituto Dermatológico de Jalisco, Avenida Federalismo Norte 3120 Col. Atemajac
del Valle Zapopan, Jalisco, Mexico 45190; Comité de Ética de la Unidad de Investigación en
AMulticenter Phase II Study to Evaluate MVA-BN in Subjects with AD
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Salud de Chihuahua, Ortiz Mena 2200, Fracc. Las Palmas, Chihuahua, Chih. Chihuahua
31205; Comité de Investigación y Bioética del Hospital Adolfo López Mateos, Av. Universidad
No. 1321, Col. Florida Mexico City, Mexico City 01030; Comité de Investigación y Ética de la
Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González" Universidad
Autónoma de Nuevo León, Av. Francisco I. Madero Pte s/n y Av.Gonzalitos s/n. Col. Mitras
Centro Monterrey, Nuevo León 64460; Comité de Ética e Investigación del Hospital Juárez de
México, Av. Instituto Politécnico Nacional #5160, Col. Magdalena de las Salinas, Mexico DF,
CP 07760; Comité de Ética del Hospital "Doctor Ángel Leaño", Av. Dr. Ángel Leaño #500 Esq.
Av. Juan Gil, Col. Los Robles, Zapopan, Jalisco, CP 45200; University of Kentucky Office of
Research Integrity and Institutional Review Board, 315 Kinkead Hall, University of Kentucky;
Lexington, KY 40506; IntegReview IRB, 3001 S. Lamar Blvd., Suite 210 Austin, TX 78704; Saint
Louis University IRB, 3556 Caroline Street; Caroline Bldg C110, St. Louis, MO 63104; and the
Northwestern University IRB, Rubloff Hall, 7th Floor; 750 N. Lake Shore Dr., Chicago, IL
60611.
Safety assessments
Safety assessments were conducted upon screening and at each of five visits during an 8 week
active study period: study visits at weeks 0 (vaccination 1), 1, 4 (vaccination 2), 6 and 8. A fol-
low-up (FU) visit or phone call was performed 28 weeks after the second vaccination. Solicited
adverse events (AEs) constituted a set of pre-defined, expected local reactions and systemic
symptoms. Solicited AEs were recorded on a diary card for the 8-day period following each
vaccination. Unsolicited AEs were all events reported by the subject within a 29-day period
after each vaccination but not already solicited in the diary card. Any cardiac symptom or elec-
trocardiogram (ECG) change which was determined to be clinically significant and any cardiac
enzyme elevation above normal were defined as AEs of special interest (AESI); cardiac enzymes
were measured routinely two weeks after each vaccination. ECG assessments were performed
at screening, week 1 and week 6. Any AEs that prevented daily activities or body
temperatures  39°C were defined as Grade 3.
Immunogenicity assays
Blood was drawn at baseline prior to the first vaccination, 1 week and 4 weeks after the first, as
well as 2 weeks and 4 weeks after the second vaccination. A sub-group of subjects had a follow-
up sample drawn at least 26 weeks after their first vaccination.
Assays for ELISA and plaque reduction neutralization test (PRNT) are described in detail
by Overton et al [30]. For the PRNT a different the detection limit (15) than described by Over-
ton et al [30] was used.
Statistical methods
The safety analysis was based on the full analysis set (FAS) consisting of all subjects who
received at least one vaccine dose. The immunogenicity analysis was performed on the per-pro-
tocol analysis set (PPS) comprising all subjects without major protocol violations. All protocol
violations were carefully reviewed on a case-by-case basis; major violations included missed
visits, missed vaccinations, missing ELISA titer data, immunosuppressive conditions or sever-
ity of illness that were exclusion criteria in the protocol, other vaccinations within 14 days of
study vaccination, errors in vaccine preparation, or participation in other studies.
All statistical analyses were performed using SAS. AEs were summarized using frequency
tables and differences between groups were tested using Fisher’s exact test. For the primary
endpoint analysis an exact 95% confidence interval for the difference in ELISA seroconversion
AMulticenter Phase II Study to Evaluate MVA-BN in Subjects with AD
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rates between healthy and AD subjects was calculated. If the lower limit of the interval was
above -5%, then non-inferiority was concluded. A similar secondary analysis was conducted on
the PRNT seroconversion rate differences. Differences in GMT were also tested using a homo-
scedastic t-test based on the log10 titers. If the lower limit of the confidence interval was above
-0.176 (corresponding to a factor 1.5) for ELISA, or -0.301 (corresponding to a factor 2) for
PRNT, then non-inferiority of the AD subjects to the healthy subjects was concluded.
The sample size calculation was based on the primary immunogenicity endpoint MVA-spe-
cific seroconversion rate. Assuming a significance level of 5%, a power of>80%, and an
expected seroconversion rates of 99% in both groups, a sample size of 124 per group (248 in
total) was estimated. In order to account for about 5% drop out rate, a total of 130 subjects per
group (260 in total) were planned to be treated. However, in order to meet the safety objective
of the trial, i.e. to detect adverse events with an incidence of at least 1:100 with 95% probability,
a total of 350 subjects were recruited in the AD group. In order to then best compare the safety
profile of the AD group to the healthy group, it was intended to recruit a roughly equal amount
of healthy subjects; however, it was also planned that the recruitment would stop once 350 sub-
jects had been recruited into the AD group.
Results
Study population
Three hundred and fifty AD subjects and 282 healthy subjects who had not been previously
vaccinated against smallpox were enrolled (Table 1). 222 subjects in the AD group (63.4%) had
active disease at the time of screening (Table 2). All 632 subjects received at least one dose of
the MVA smallpox vaccine. Fig 1 displays the disposition of subjects. Follow-up data were col-
lected by a telephone contact 28 weeks after the second vaccination for 321 AD and 272 healthy
subjects. For a subset of 76 AD and 94 healthy subjects there was an on-site visit to collect
serum for immunogenicity studies.
Subject demographics and SCORAD status
Mean age, height and weight were similar in both groups. Some differences between the groups
were observed in ethnic origin and gender distribution (Table 1). The mean SCORAD value of
subjects with a SCORAD>0 was 18.6 ± 8.29 at screening, i.e. mild to moderate disease
(Table 2). At Week 8 the number of subjects with a SCORAD> 0 was lower and their mean
SCORAD was 15.7 ± 8.61, suggesting that MVA did not exacerbate the underlying disease.
Safety and reactogenicity
Overview of adverse events (AEs). An overview of the incidence of all AEs is presented in
Table 3. No case of death, EV or myopericarditis occurred. There was no statistically significant
difference in the frequency of AESI in both groups. The trial had been designed to detect, with a
95% probability, any safety signal occurring with a frequency of at least 1%. During the active
study period, three subjects experienced a total of four serious AEs. Only one event, extraocular
muscle paresis in a healthy subject, was considered as probably related to the study vaccine. One
healthy subject was withdrawn from the study due to several AEs (arthralgia, nausea, abdominal
pain) considered unlikely related to the study vaccine. AD subjects experienced causally related
AEs more frequently than healthy subjects (67.4% vs 59.6%; p = 0.046, Table 3). However, this
difference was mostly due to events of mild and moderate intensity. There was no statistically sig-
nificant difference between the two groups in the proportion of subjects with Grade 3 causally
related AEs (7.7% vs 5.7%; p = 0.343; AD vs healthy).
AMulticenter Phase II Study to Evaluate MVA-BN in Subjects with AD
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Solicited adverse events. As expected, most subjects in both groups experienced at least
one solicited local AE (injection site pain, injection site erythema or injection site swelling,
Table 4). Local AEs were most often of Grade 1 intensity except for injection site pain, which
Table 1. Demographic data.
(FAS, N = 632) Diagnosed AD (N = 350) Healthy (N = 282) p-Value
Age [years] Mean ± SD 27.9 ± 6.33 27.4 ± 5.81 0.3095
Median 27.0 26.6
Range 18–42 18–41
Gender [n (%)] Female 223 (63.7) 150 (53.2) 0.0092
Male 127 (36.3) 132 (46.8)
Height [cm] Mean ± SD 166.9 ± 10.06 169.6 ± 9.72 0.0005
Median 166.0 169.0
Range 137–201 145–195
Weight [kg]a Mean ± SD 73.19 ± 17.950 77.49 ± 19.779 0.0044
Median 70.30 74.80
Range 40.9–138.8 40.9–175.0
Body mass index [kg/m2]a Mean ± SD 26.20 ± 5.850 26.82 ± 6.132 0.1988
Median 25.00 25.35
Range 15.9–55.3 15.7–64.3
Ethnic origin [n (%)] Black 33 (9.4) 24 (8.5) 0.0036
Caucasian 125 (35.7) 124 (44.0)
Hispanic 134 (38.3) 109 (38.7)
Oriental/ Asian 49 (14.0) 20 (7.1)
Other 9 (2.6) 5 (1.8)
(PPS, N = 451) Diagnosed AD (N = 257) Healthy (N = 194) p-Value
Age [years] Mean ± SD 27.6 ± 6.20 27.2 ± 5.96 0.4618
Median 26.5 26.2
Range 18–42 18–41
Gender [n (%)] Female 165 (64.2) 101 (52.1) 0.0119
Male 92 (35.8) 93 (47.4)
Height [cm] Mean ± SD 167.3 ± 10.18 170.3 ± 10.12 0.0023
Median 166.0 170.0
Range 138–201 145–195
Weight [kg]a Mean ± SD 74.25 ± 18.24 76.92 ± 18.792 0.1370
Median 72.00 74.80
Range 40.9–138.8 43.7–175.0
Body mass index [kg/m2]a Mean ± SD 26.43 ± 5.913 26.44 ± 5.854 0.9960
Median 25.30 25.15
Range 15.9–55.3 15.7–64.3
Ethnic origin [n (%)] Black 26(10.1) 15 (7.7) 0.0010
Caucasian 97 (37.7) 79 (40.7)
Hispanic 86 (33.5) 85 (43.8)
Oriental/ Asian 40 (15.6) 12 (6.2)
Other 8 (3.1) 3 (1.5)
N = number of subjects in the specified group; n = number of subjects in the specified category; % = percentages of n based on N; AD = atopic dermatitis;
FAS = full analysis set; SD = standard deviation
a: weight determined at screening visit. PPS = Per Protocol analysis set.
doi:10.1371/journal.pone.0138348.t001
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was experienced by most individuals with Grade 2 or 3 intensity. Statistically significant differ-
ences between the groups were seen for injection site erythema (p = 0.004) and injection site
swelling (p = 0.005). Solicited systemic AEs (Table 5) were more frequent in subjects diagnosed
with AD (70.1%) compared to healthy subjects (56.4%), a statistically significant difference
(p< 0.001). The majority of solicited systemic AEs were considered to be causally related to
the study vaccine. The duration of both solicited systemic and local AEs was similar in both
groups. Taken together, the data indicate that AD subjects have slightly more solicited AEs
with more intense reactions towards MVA than healthy subjects.
Unsolicited adverse events. Unsolicited AEs experienced by 2% of subjects in any study
group are presented in Table 6. A similar percentage of subjects reported at least one unsolic-
ited AE (68.6% in subjects with diagnosed AD and 64.5% in healthy subjects), with most events
being classified as 'systemic disorders and administration site conditions'. This was mostly due
to a high rate of 'injection site pruritus', which was reported by 28.6% of the subjects in the AD
group and by 17.0% of the healthy subjects, a statistically significant difference (p< 0.001).
Rashes were observed only in isolated cases, with no trend towards a specific treatment group.
In addition, AEs classified as 'skin and subcutaneous tissue disorders' were reported more fre-
quently by AD than by healthy subjects (p = 0.002). Overall, more than two thirds of all unso-
licited AEs in both groups were of Grade 1 intensity and Grade 3 AEs were reported in both
groups with a similar frequency. Unsolicited AEs assessed as being probably or definitely
related to the study vaccine occurred in 31.8% of the AD and 22.5% of the healthy subjects
(p = 0.007) and they were usually associated with direct injection site reactions. Overall AD
subjects had more skin reactions possibly, probable or definite related to the vaccine than
healthy subjects, but these reactions were mostly mild or moderate and did not prevent daily
activities.
Cardiac events. To determine the cardiac risk, any cardiac symptom, ECG change deter-
mined to be clinically significant, cardiac enzyme or troponin I level elevated above normal,
was noted as an AESI. When AESI persisted, or if clinically indicated, the subjects were referred
to a cardiologist. A transient increase in troponin I was measured for about the same percent-
age of subjects diagnosed with AD (15.4%) as for healthy subjects (13.1%, Table 6).
In the AD group, four subjects presented with one AESI each other than an increased Tro-
ponin I: Tachycardia and QTc prolongation of>440 msec, both assessed as unlikely related,
and T wave inversion and palpitations, both considered possibly related to the study vaccine.
The case of palpitations was assessed as benign by a cardiologist and symptoms resolved suc-
cessfully after treatment with atenolol. A precise cause for the palpitations was not identified;
Table 2. Atopic dermatitis status.
Screening N = 350 Week 8 N = 325 P-value
AD currently active n (%) 222 (63.4) 139 (42.8) < 0.001
SCORAD (subjects with SCORAD >0 only) n 220 (62.9) 136 (41.2) < 0.001
Mean ± SD 18.6 ± 8.29 15.7 ± 8.61 < 0.001
Median 19.0 15.0
Range 0-70a 0-45a
N = number of subjects in the specified group; n = number of subjects in the specified category; % = percentages of n based on N; AD = atopic dermatitis;
SD = standard deviation; SCORAD = Scoring Atopic Dermatitis; a: 10 subjects with currently active AD had a SCORAD >30 at screening. The SCORAD is
a rather subjective assessment tool. A baseline SCORAD up to 39 was considered as a minor and a baseline SCORAD > 39 as a major protocol
violation. This allows for a variability of 30% in SCORAD assessment. 2 of these subjects had a SCORAD >39 and were excluded from PPS as major
protocol violations. P-value is Fisher’s exact test of the differences in proportions between groups or a t-test of difference in the mean SCORAD values.
doi:10.1371/journal.pone.0138348.t002
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Fig 1. Disposition of subjects. AD = atopic dermatitis; n = number of subjects in the specified category; FAS = full analysis set; PPS = per-protocol analysis
set. a: There was one subject that did not receive the second vaccination but did not terminate the study prematurely, i.e. returned for the final visit. b: more
than one reason per subject possible. c: 10 subjects with currently active AD had a SCORAD >30 at screening; 2 of these subjects had a SCORAD >39 and
A Multicenter Phase II Study to Evaluate MVA-BN in Subjects with AD
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however tests indicated that the subject’s thyroid values were at the upper limit of normal and
the ongoing concomitant medication with albuterol may have contributed. A second case of
tachycardia, assessed as unrelated to the study vaccine, was recorded for one healthy subject at
a follow-up visit. The heart rate had returned to normal at an additional visit. In total, four sub-
jects were referred to a cardiologist, but with the exception of the case mentioned above, no car-
diac treatment was prescribed. All events resolved without sequelae.
Serious adverse events (SAEs). During the active study period, one subject with active AD
and two healthy subjects experienced a total of four SAEs. Three of them (head injury, loss of
consciousness, panic attack) were assessed as not related to the study vaccine. One SAE (extra-
ocular muscle paresis) occurring 8 days after the second vaccination was noted as probably
related to the vaccine. The subject was a 28 year old healthy woman who complained of con-
stant mixed horizontal and vertical diplopia. The ophthalmologist treated her with carbamaze-
pine and vitamin B complex and the event resolved without sequelae. After Week 8, one
healthy subject and two subjects with active AD experienced a total of four SAEs (pneumonia,
asthma attack in a subject with a history of asthma, and two events of psychoneurotic disorder
in one subject); all were assessed as not related to the study vaccine.
Immunogenicity
ELISA and PRNT seroconversion rates were similar for both groups at all time points (Fig 2A
and 2B, Table 7). ELISA seroconversion rates peaked two weeks post second vaccination when
97.2% of AD subjects and 98.1% of healthy subjects had seroconverted. The primary endpoint
of the trial was met because the ELISA seroconversion rate for AD subjects two weeks post sec-
ond vaccination was non-inferior compared to that for healthy subjects. PRNT seroconversion
rates peaked two weeks post second vaccination with 88.0% of the AD group and 86.0% of the
healthy group seroconverting. The PRNT seroconversion rate for AD subjects two weeks post
second vaccination was also non-inferior compared to that for healthy subjects.
GMTs determined by ELISA were similar for both groups at all visits, reaching a peak of
516.0 at Week 6 for the AD group, which was non-inferior to the peak of 508.8 for the healthy
group (Fig 3A, Table 8) (p<0.0001). The peak GMT determined by PRNT for the AD group
was non-inferior compared to that of the healthy group at Week 6 (GMT of 43.0 and 38.5 in
were excluded from PPS as major protocol violations. For the volunteers that were excluded from the PPS but had samples available, immunogenicity results
were similar to those of the PPS subjects.
doi:10.1371/journal.pone.0138348.g001
Table 3. Subjects Experiencing at Least One Unsolicited or Solicited Adverse Events (FAS, N = 632).
Subject based Diagnosed AD (N = 350) n (%) Healthy (N = 282) n (%) P-value
At least one AE documented 331 (94.6) 268 (95.0) 0.858
SAE in active study period 1 (0.3) 2 (0.7) 0.589
AESI 58 (16.6) 38 (13.5) 0.316
AE leading to withdrawal from study 0 (0.0) 1 (0.4) 0.446
Causally related AE 236 (67.4) 168 (59.6) 0.046
Causally related AE graded  3 27 (7.7) 16 (5.7) 0.343
N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one adverse event); % = percentages of n
based on N; AD = atopic dermatitis; AE = adverse event; AESI = adverse event of special interest; SAE = serious adverse event; related AE = AE
considered by the investigator to have a possible, probable, definite or missing relationship to study medication; Grade  3 = AE which prevented normal
everyday activities or body temperature  39°C; FAS = full analysis set. P-value is Fisher’s exact test of the differences in proportions between groups.
doi:10.1371/journal.pone.0138348.t003
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the AD and healthy groups respectively, (p<0.0001)). Again, the GMTs on all other visits were
similar for both groups. Combining both groups, there was a statistically significant correlation
between ELISA and PRNT results (Fig 3B) at all time points, with Spearman correlation coeffi-
cients ranging from between 0.40 to 0.65 at the different time points. Maximum correlation
was at the peak visit two weeks after the second vaccination.
Table 4. Subjects Experiencing at Least One Solicited Local Adverse Event (8-Day Follow-Up Period after Vaccination, FAS, N = 632).
Solicited Local Event Intensity/Size Diagnosed AD N = 345 n (%) Healthy N = 282 n (%) P-value
Injection Site Pain Total 283 (82.0) 233 (82.6) 0.916
Grade  2a 152 (44.1) 117 (41.5) 0.570
Grade  3b 53 (15.4) 31 (11.0) 0.126
Injection Site Erythema Total 211 (61.2) 139 (49.3) 0.004
 30 mm (Grade 2) 66 (19.1) 35 (12.4) 0.029
 100 mm (Grade 3) 3 (0.9) 3 (1.1) 1.000
Injection Site Swelling Total 180 (52.2) 115 (40.8) 0.005
 30 mm (Grade 2) 45 (13.0) 21 (7.4) 0.026
 100 mm (Grade 3) 1 (0.3) 2 (0.7) 0.591
N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one report of a local adverse event); % =
percentages of n based on N; AD = atopic dermatitis; AE = adverse event. FAS = full analysis set
a: Injection Site Pain grade 2: pain when moving the limb
b: Injection Site Pain grade 3: spontaneously painful. P-value is Fisher’s exact test of the differences in proportions between groups.
doi:10.1371/journal.pone.0138348.t004
Table 5. Subjects Experiencing at Least One Solicited Systemic Adverse Events (8-Day Follow-Up period After Vaccination, FAS, N = 632).
Solicited Systemic Adverse Event Intensity Diagnosed AD N = 345 n (%) Healthy N = 282 n (%) P-value
Any Solicited AE 242 (70.1) 159 (56.4) 0.001
Body temperature increase Total number 28 (8.1) 23 (8.2) 1.000
 39.0°C 1 (0.3) 1 (0.4) 1.000
Grade  3 (related) 1 (0.3) 1 (0.4) 1.000
Headache Total number 163 (47.2) 98 (34.8) 0.002
Grade  3 26 (7.5) 9 (3.2) 0.022
Grade  3 (related) 18 (5.2) 5 (1.8) 0.031
Myalgia Total number 153 (44.3) 98 (34.8) 0.018
Grade  3 14 (4.1) 9 (3.2) 0.671
Grade  3 (related) 9 (2.6) 8 (2.8) 1.000
Chills Total number 55 (15.9) 22 (7.8) 0.002
Grade  3 7 (2.0) 4 (1.4) 0.762
Grade  3 (related) 3 (0.9) 4 (1.4) 0.707
Nausea Total number 80 (23.2) 41 (14.5) 0.008
Grade  3 8 (2.3) 6 (2.1) 1.000
Grade  3 (related) 5 (1.4) 4 (1.4) 1.000
Fatigue Total number 124 (35.9) 75 (26.6) 0.013
Grade  3 16 (4.6) 9 (3.2) 0.416
Grade  3 (related) 9 (2.6) 5 (1.8) 0.592
N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one report of a solicited systemic AE); % =
percentages of n based on N; AD = atopic dermatitis; AE = adverse event; Grade  3 = AE which prevented normal everyday activities or body
temperature  39°C; related AE = AE considered by the investigator to have a possible, probable or definite relationship to study medication.
doi:10.1371/journal.pone.0138348.t005
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Discussion
This Phase II trial confirmed the observations from a Phase I trial that the safety and immuno-
genicity of MVA in individuals with active AD or a history of AD is similar to healthy individu-
als [23]. Unsolicited and solicited AEs reported during the study were consistent with results
obtained from previously completed clinical trials with MVA [19–23].
The number of serious AEs was low, just one serious AE involving transitory ocular paraly-
sis was assessed as probably related to the study vaccine. The impairment was limited to the
extraocular inferior rectal muscle which recovered without sequelae. To date, no other similar
event has been observed following administration of MVA. No other serious AE with a possi-
ble, probable or definite causal relationship occurred in the AD group, indicating with a 95%
certainty that the rate of such events in subjects with AD is less than 1%.
Table 6. Subjects Experiencing at Least One Unsolicited Adverse Events (Occurring in 2% of Subjects in any Study Group, FAS, N = 632).
System organ class Preferred term (MedDRA 9.0) Diagnosed AD (N = 350) n (%) Healthy (N = 282) n (%) p-Value
At least one unsolicited AE 240 (68.6) 182 (64.5) 0.3083
Unsolicited AE Grade 1 298 (68.5) 432 (80.1) 0.1108
Unsolicited AE Grade 3 29 (6.7) 21 (3.9) 0.7627
Systemic disorders and administration site conditions 119 (34.0) 65 (23.0) 0.0027
Injection site pruritus 100 (28.6) 48 (17.0) 0.0007
Injection site bruising 7 (2.0) 2 (0.7) 0.3114
Injection site induration 3 (0.9) 6 (2.1) 0.1977
Investigations 63 (18.0) 46 (16.3) 0.5979
Troponin I increased 54 (15.4) 37 (13.1) 0.4273
Infections and infestations 56 (16.0) 55 (19.5) 0.2930
Nasopharyngitis 23 (6.6) 11 (3.9) 0.1582
Influenza 11 (3.1) 8 (2.8) 1.0000
Upper respiratory tract infection 6 (1.7) 9 (3.2) 0.2946
Pharyngitis 4 (1.1) 9 (3.2) 0.0916
Pharyngotonsillitis 3 (0.9) 7 (2.5) 0.1196
Gastrointestinal disorders 30 (8.6) 29 (10.3) 0.4933
Diarrhoea 9 (2.6) 7 (2.5) 1.0000
Nervous system disorders 29 (8.3) 27 (9.6) 0.5766
Headache 16 (4.6) 19 (6.7) 0.2940
Dizziness 11 (3.1) 7 (2.5) 0.8107
Skin and subcutaneous tissue disorders 35 (10.0) 10 (3.5) 0.0017
Dermatitis atopica 15 (4.3) 0 (0.0) 0.0002
Respiratory, thoracic and mediastinal disorders 16 (4.6) 25 (8.9) 0.0345
Cough 3 (0.9) 8 (2.8) 0.0705
Pharyngolaryngeal pain 2 (0.6) 8 (2.8) 0.0275
Rhinorrhoea 3 (0.9) 6 (2.1) 0.1977
Musculoskeletal and connective tissue disorders 13 (3.7) 19 (6.7) 0.1008
Injury, poisoning and procedural procedures 9 (2.6) 15 (5.3) 0.0932
Reproductive system and breast disorders 9 (2.6) 11 (3.9) 0.3683
Dysmenorrhoea 8 (2.3) 7 (2.5) 1.0000
Psychiatric disorders 7 (2.0) 9 (3.2) 0.4464
Eye disorders 7 (2.0) 3 (1.1) 0.5243
N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one report of a unsolicited AE); % =
percentages of n based on N; AD = atopic dermatitis; AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; FAS = full analysis set.
doi:10.1371/journal.pone.0138348.t006
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Not surprisingly, AD subjects were more likely to develop 'injection site erythema' and
'injection site swelling'. However, there was no indication that vaccination with MVA worsened
the intensity of AD. Some subjects in the AD group experienced a flare-up or worsening of
their disease during the study, while others with active AD at screening did not show any active
AD at the end of the study. This may reflect the nature of the underlying disease, which shows
episodes of exacerbations as well as periods of remission [31].
While the burden of AD in the adult population is not as well characterized as in pediatric
populations, based on SCORAD the population enrolled in this study was similar to the distri-
bution of AD reported in pediatric populations [32,33]. Although individuals with severe AD
(SCORAD>30) were per protocol excluded from this trial, there was no signal in this trial to
suggest that MVA would not be safe for them. Historically, the severity of AD has not been
associated with increased occurrence or greater severity of complications resulting from small-
pox vaccination. Both persons with a history of active disease or with active disease are at risk
of developing EV, suggesting an underlying “genetic” susceptibility might be the most impor-
tant factor for vaccination side-effects [6]. As MVA does not replicate in human cells and is
administered subcutaneously rather than by scarification, MVA vaccination should not result
in any of the other adverse events associated with virus replication. While the trial was not
large enough to draw definitive conclusions, it is reassuring that no case of EV or any other rep-
lication-associated adverse event occurred.
Smallpox vaccination using replicating vaccines conducted in recent years resulted in cases
of myopericarditis that clustered during the second week after vaccination. The occurrence of
vaccine associated myopericarditis was confirmed at a rate of 5.73 per 1,000 vaccinia-naïve vac-
cinees who received ACAM2000 [34,35]. Cardiac monitoring during the present trial revealed
no cardiac risks related to the use of MVA, consistent with published data on cardiac monitor-
ing following administration of MVA [36]. The vast majority of cardiac related events were
Grade 1 events ('troponin I increased') that were transient and not connected to abnormal
ECG findings or any cardiac symptom [37].
Fig 2. Seroconversion. Seroconversion rates were determined by vaccinia-specific ELISA (A) and PRNT (B). Data set is FAS (full analysis set), N = 632 (for
Week 32 N = 235). Error bars represent upper and lower confidence intervals. Vaccinations were given at Week 0 andWeek 4. AD = atopic dermatitis.
doi:10.1371/journal.pone.0138348.g002
Table 7. Seroconversion rates for ELISA and PRNT at all post-baseline visits (FAS, N = 632).
Week Diagnosed AD (N = 350) n SC (%) Healthy (N = 282) n SC (%) Difference in SC rates (95% CI) (AD–Healthy)
ELISA
Week 1 333 74 (22.2) 267 39 (14.6) 7.6 (1.4, 13.8)
Week 4 328 276 (84.1) 273 233 (85.3) -1.2 (-7.0,4.7)
Week 6 325 316 (97.2) 265 260 (98.1) -0.9 (-3.7,1.9)
Week 8 325 311 (95.7) 264 254 (96.2) -0.5 (-3.9, 2.9)
Week 32 111 80 (72.1) 124 87 (70.2) 1.9 (-9.9, 13.7)
PRNT
Week 1 333 20 (6.0) 267 13 (4.9) 1.1 (-2.7, 4.9)
Week 4 327 81 (24.8) 273 64 (23.4) 1.3 (-5.6, 8.2)
Week 6 325 286 (88.0) 265 228 (86.0) 2.0 (-3.5, 7.6)
Week 8 325 253 (77.8) 264 197 (74.6) 3.2 (-3.7,10.2)
Week 32 111 27 (24.3) 124 30 (24.2) 0.1 (-11.0, 11.3)
N = number of subjects in the specified group; n = number of subjects who had a titer available at the specified visit; SC is the number of subjects who
had seroconverted.
doi:10.1371/journal.pone.0138348.t007
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The trial confirmed that AD subjects were able to generate humoral vaccinia-specific
immune responses at levels similar to healthy subjects, confirming earlier results in subjects
with mild AD [31]. Although individuals with severe AD (SCORAD>30) were not under
investigation in this the trial, it is likely that they would mount a comparable immunological
response, as there is little evidence suggesting that AD has any measurable impact on immuno-
logical responses to vaccines delivered subcutaneously [38].
In summary, vaccination with MVA was equally well tolerated in both populations and elic-
ited a robust vaccinia-specific immune response. The observation that vaccination does not
have any discernible impact on the status or severity of AD suggests that MVA may represent a
safer alternative to replication-competent vaccinia vaccines for individuals with AD.
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Table 8. GMT for ELISA and PRNT at all post-baseline visits (FAS, N = 632).
Week Diagnosed AD (N = 350) GMT
(95% CI)
Healthy (N = 282) GMT
(95% CI)
Ratio of GMTs (95% CI) (AD /
Healthy)
ELISA
Week 0 1.7 (1.5, 2.0) 1.4 (1.2, 1.6) 1.211 (0.984, 1.489)
Week 1 3.4 (2.7, 4.3) 2.5 (2.0, 3.1) 1.387 (1.004, 1.916)
Week 4 59.7 (49.2, 72.4) 59.7 (48.8, 73.1) 0.999 (0.755, 1.324)
Week 6 516.0 (449.7, 592.0) 508.8 (432.2, 598.9) 1.014 (0.821, 1.253)
Week 8 285.8 (247.6, 329.8) 283.8 (240.8, 334.6) 1.007 (0.811, 1.251)
Week
32
30.0 (21.0, 42.7) 22.8 (16.0, 32.4) 1.314 (0.798, 2.163)
PRNT
Week 0 1.2 (1.1, 1.3) 1.1 (1.0, 1.2) 1.103 (0.982, 1.238)
Week 1 1.4 (1.2, 1.7) 1.3 (1.1, 1.5) 1.121 (0.924, 1.359)
Week 4 2.6 (2.1, 3.1) 2.2 (1.9, 2.7) 1.444 (0.868, 1.508)
Week 6 43.0 (35.0, 52.8) 35.5 (28.1, 44.7) 1.213 (0.890, 1.653)
Week 8 19.7 (15.9, 24.3) 14.8 (11.8, 18.6) 1.329 (0.971, 1.819)
Week
32
2.4 (1.8, 3.3) 2.3 (1.7, 3.0) 1.074 (0.713, 1.618)
N = number of subjects in the specified group.
doi:10.1371/journal.pone.0138348.t008
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